|
1
|
Essig S, Li Q, Chen Y, Hitzler J,
Leisenring W, Greenberg M, Sklar C, Hudson MM, Armstrong GT, Krull
KR, et al: Risk of late effects of treatment in children newly
diagnosed with standard-risk acute lymphoblastic leukaemia: A
report from the Childhood Cancer Survivor Study cohort. Lancet
Oncol. 15:841–851. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Turcotte LM and Neglia JP: Survivors of
childhood cancer: Risk of new primary neoplasms of the CNS. Tumors
of the Central Nervous System. Hayat MA: ISSN: 2215-096X12.
Springer; Dordrecht: pp. 137–pp145. 2014, View Article : Google Scholar
|
|
3
|
McCarthy PL, Owzar K and Hahn T:
Autologous hematopoietic stem cell transplantation and maintenance
therapy for multiple myeloma. Int J Hematol Oncol. 2:71–83. 2013.
View Article : Google Scholar
|
|
4
|
Rein LA, Sung AD and Rizzieri DA: New
approaches to manipulate minimal residual disease after allogeneic
stem cell transplantation. Int J Hematol Oncol. 2:39–48. 2013.
View Article : Google Scholar
|
|
5
|
Duncan C and Roddie H: Dendritic cell
vaccines in acute leukaemia. Best Pract Res Clin Haematol.
21:521–541. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Conrad DP, Tsang J, Maclean M, Diallo JS,
Le Boeuf F, Lemay CG, Falls TJ and Parato KA: Leukemia
cell-rhabdovirus vaccine: Personalized immunotherapy for acute
lymphoblastic leukemia. Clin Cancer Res. 19:3832–3843. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pospísilová D, Borovicková J, Poloucková
A, Spísek R, Sedivá A, Hrusák O, Starý J and Bartůnková J:
Generation of functional dendritic cells for potential use in the
treatment of acute lympho-blastic leukemia. Cancer Immunol
Immunother. 51:72–78. 2002. View Article : Google Scholar
|
|
8
|
Maggio R, Peragine N, Calabrese E, De
Propris MS, Intoppa S, Della Starza I, Ariola C, Vitale A, Foà R
and Guarini A: Generation of functional dendritic cells (DC) in
adult acute lymphoblastic leukemia: Rationale for a DC-based
vaccination program for patients in complete hematological
remission. Leuk Lymphoma. 48:302–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malissen B, Tamoutounour S and Henri S:
The origins and functions of dendritic cells and macrophages in the
skin. Nat Rev Immunol. 14:417–428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma Y, Aymeric L, Locher C, Kroemer G and
Zitvogel L: The dendritic cell-tumor cross-talk in cancer. Curr
Opin Immunol. 23:146–152. 2011. View Article : Google Scholar
|
|
11
|
Palucka K and Banchereau J: Cancer
immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Subklewe M, Geiger C, Lichtenegger FS,
Javorovic M, Kvalheim G, Schendel DJ and Bigalke I: New generation
dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
Cancer Immunol Immunother. 63:1093–1103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anton D, Dabadghao S, Palucka K, Holm G
and Yi Q: Generation of dendritic cells from peripheral blood
adherent cells in medium with human serum. Scand J Immunol.
47:116–121. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jeras M, Bergant M and Repnik U: In vitro
preparation and functional assessment of human monocyte-derived
dendritic cells-potential antigen-specific modulators of in vivo
immune responses. Transpl Immunol. 14:231–244. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bach JF: Thymic hormones. J
Immunopharmacol. 1:277–310. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Goldstein AL, Guha A, Zatz MM, Hardy MA
and White A: Purification and biological activity of thymosin, a
hormone of the thymus gland. Proc Natl Acad Sci USA. 69:1800–1803.
1972. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Romani L, Bistoni F, Montagnoli C, Gaziano
R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E, et
al: Thymosin alpha1: An endogenous regulator of inflammation,
immunity, and tolerance. Ann N Y Acad Sci. 1112:326–338. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan Y, Chang H, Yu Y, Liu J and Wang R:
Thymosin α 1 suppresses proliferation and induces apoptosis in
human leukemia cell lines. Peptides. 27:2165–2173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin JJ, Hsu HY, Yang JS, Lu KW, Wu RS, Wu
KC, Lai TY, Chen PY, Ma CY, Wood WG, et al: Molecular evidence of
anti-leukemia activity of gypenosides on human myeloid leukemia
HL-60 cells in vitro and in vivo using a HL-60 cells murine
xenograft model. Phytomedicine. 18:1075–1085. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fidan I, Yesilyurt E, Kalkanci A, Aslan
SO, Sahin N, Ogan MC and Dizbay M: Immunomodulatory effects of
voriconazole and caspofungin on human peripheral blood mononuclear
cells stimulated by Candida albicans and Candida krusei. Am J Med
Sci. 348:219–223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao Q, Doan LX, Zhang R, Bharadwaj U, Li M
and Chen C: Thymosin-alpha1 modulates dendritic cell
differentiation and functional maturation from human peripheral
blood CD14+ monocytes. Immunol Lett. 110:110–120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisen S, Wedner H and Parker C: Isolation
of pure human pexipherac blood T-lymphocytes using nylon wool
columns. Immunol Invest. 1:571–577. 1972. View Article : Google Scholar
|
|
23
|
Timmerman JM and Levy R: Dendritic cell
vaccines for cancer immunotherapy. Annu Rev Med. 50:507–529. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Banchereau J and Palucka AK: Dendritic
cells as therapeutic vaccines against cancer. Nat Rev Immunol.
5:296–306. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sabado RL, Miller E, Spadaccia M, Vengco
I, Hasan F and Bhardwaj N: Preparation of Tumor Antigen-loaded
Mature Dendritic Cells for Immunotherapy. J Vis Exp. View Article : Google Scholar : 2013.PubMed/NCBI
|
|
26
|
Huang Y, Chen Z, Zhou C, Yao H, Li M and
Xu C: The modulation of thymosin alpha 1 in the maturation,
differentiation and function of murine bone marrow-derived
dendritic cells in the absence or presence of tumor necrosis
factor-alpha. Int Immunopharmacol. 4:539–546. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ragde H, Cavanagh WA and Tjoa BA:
Dendritic cell based vaccines: Progress in immunotherapy studies
for prostate cancer. J Urol. 172:2532–2538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu S, Yu Y, Zhang M, Wang W and Cao X:
The involvement of TNF-alpha-related apoptosis-inducing ligand in
the enhanced cytotoxicity of IFN-beta-stimulated human dendritic
cells to tumor cells. J Immunol. 166:5407–5415. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
MartIn-Fontecha A, Sebastiani S, Höpken
UE, Uguccioni M, Lipp M, Lanzavecchia A and Sallusto F: Regulation
of dendritic cell migration to the draining lymph node: Impact on T
lymphocyte traffic and priming. J Exp Med. 198:615–621. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
de Vries IJ, Lesterhuis WJ, Scharenborg
NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM,
Torensma R, Adema GJ, et al: Maturation of dendritic cells is a
prerequisite for inducing immune responses in advanced melanoma
patients. Clin Cancer Res. 9:5091–5100. 2003.PubMed/NCBI
|
|
31
|
León B and Ardavín C: Monocyte-derived
dendritic cells in innate and adaptive immunity. Immunol Cell Biol.
86:320–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slukvin II, Thomson JA, Vodyanyk MA and
Gumenyuk ME: Method of forming dendritic cells from embryonic stem
cells. US Patent no 8,785,189. Washington, DC: U.S. Patent and
Trademark Office; 2014, Filed Feb 1, 2012; issued May 7, 2013.
|
|
33
|
Cao X, Sugita M, van der Wel N, Lai J,
Rogers RA, Peters PJ and Brenner MB: CD1 molecules efficiently
present antigen in immature dendritic cells and traffic
independently of MHC class II during dendritic cell maturation. J
Immunol. 169:4770–4777. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tan SM, Kapp M, Flechsig C, Kapp K, Rachor
JE, Eyrich M, Loeffler J, Einsele H and Grigoleit GU: Stimulating
surface molecules, Th1-polarizing cytokines, proven trafficking-a
new protocol for the generation of clinical-grade dendritic cells.
Cytotherapy. 15:492–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
van der Wel NN, Sugita M, Fluitsma DM, Cao
X, Schreibelt G, Brenner MB and Peters PJ: CD1 and major
histocompatibility complex II molecules follow a different course
during dendritic cell maturation. Mol Biol Cell. 14:3378–3388.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lechmann M, Berchtold S, Steinkasserer A
and Hauber J: CD83 on dendritic cells: More than just a marker for
maturation. Trends Immunol. 23:273–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prechtel AT, Turza NM, Theodoridis AA and
Steinkasserer A: CD83 knockdown in monocyte-derived dendritic cells
by small interfering RNA leads to a diminished T cell stimulation.
J Immunol. 178:5454–5464. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Drénou B, Amiot L, Setterblad N, Taque S,
Guilloux V, Charron D, Fauchet R and Mooney N: MHC class II
signaling function is regulated during maturation of plasmacytoid
dendritic cells. J Leukoc Biol. 77:560–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li XL, Zhao YX, Sun LR, Yang J and Xu HJ:
The preparation of HL-60 cells vaccine expressing BCG heat shock
protein 70 and detection of its immunogenicity in vitro. Hum Vaccin
Immunother. 8:1376–1381. 2012. View
Article : Google Scholar : PubMed/NCBI
|
